1-4 of 4
Hamadi Zouabi, MD
Close
Sort by
Journal Articles

A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study

Carol Moreno, MD, Marco Montillo, MD, Panayiotidis Panayiotis, MD, Adrian Bloor, PhD, FRCP, FRCPath, Jehan Dupuis, MD, Anna Schuh, MD, PhD, Stefan Norin, MD, Christian H Geisler, Peter Hillmen, MB ChB, PhD, Michael Doubek, Prof., Petra Obrtlikova, MD, Luca Laurenti, MD, Stephan Stilgenbauer, MD, Lukas Smolej, MD, PhD, Paolo Ghia, MD, PhD, Florence Cymbalista, MD, PhD, Ulrich Jaeger, Niki Stavroyianni, Patrick Carrington, MD, Hamadi Zouabi, MD, Veronique Leblond, MD, Juan Carlos Gomez, MD, Roberto Marasca, MD, Gerardo Musuraca, MD, PHD, Luigi Rigacci, MD, Lucia Farina, Rossella Paolini, Sarka Pospisilova, Prof., Eva Kimby, MD, Colm Bradley, Emili Montserrat, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1645.
https://doi.org/10.1182/blood.V122.21.1645.1645
Published: 2013
Journal Articles

I.V. Busulfan Given Based on Body Weight in Combination with Cyclophosphamide in Children: Pharmacokinetic and Clinical Results of a Myeloablative, Reduced-Toxicity Conditioning Regimen for Allogeneic Stem Cell Transplantation.

Helene Esperou, MD, Bénédicte Neven, MD, Karima Yakouben, MD, Claire Galambrun, MD, Françoise Méchinaud, MD, Catherine Paillard, MD, Pierre Bordigoni, MD, Hamadi Zouabi, MD, Laurent Nguyen, PharD, Gérard Michel, MD, Gilles Vassal, MD PhD
Journal: Blood
Blood (2006) 108 (11): 5131.
https://doi.org/10.1182/blood.V108.11.5131.5131
Published: 2006
Journal Articles

A New IV Busulfan Fixed Dosing as Part of BuMel or BuCy Conditioning Regimens: A Pharmacokinetic/Pharmacodynamic Study in Pediatric Patients Undergoing Autologous or Allogeneic Hematopoietic Stem Cell Transplantation.

Gilles Vassal, MD, PhD, Hélène Esperou, MD, Dominique Valteau-Couanet, MD, Jean Claude Gentet, MD, François Doz, MD, Françoise Méchinaud, MD, Claire Galambrun, MD, Alain Fischer, MD, Hamadi Zouabi, MD, Laurent Nguyen, Pharm D, Gérard Michel, MD
Journal: Blood
Blood (2005) 106 (11): 5200.
https://doi.org/10.1182/blood.V106.11.5200.5200
Published: 2005
Journal Articles

A New Busulfan Fixed Dosing for Conditioning before Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children with Malignant and Non-Malignant Diseases: Pharmacokinetics, Toxicity and Clinical Outcomes.

Gérard Michel, MD, Dominique Valteau-Couanet, MD, Hélène Esperou, MD, Jean Claude Gentet, MD, François Doz, MD, Françoise Méchinaud, MD, Claire Galambrun, MD, Alain Fischer, MD, Hamadi Zouabi, MD, Christian Puozzo, PhD, Gilles Vassal, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 1758.
https://doi.org/10.1182/blood.V106.11.1758.1758
Published: 2005